Investor Presentation Q1 2023

75 Investor presentation First three months of 2023 Novo NordiskⓇ In the Explorer 7 trial, concizumab reduced the number of bleeds. in adults and adolescents with inhibitors Explorer 7 trial results: Annualised bleeding rate per patient group Annualised Bleeding Rate (ABR) 100 90 40 40 30 20 20 10 9.8 Median Mean 0 OnD treatment PPX treatment PPX treatment HWI (Group 2) HAWI (Groups 1-4) PPX treatment HBWI (Groups 1-4) HWI (Group 1) Efficacy • Key highlights Median ABR was 0 for concizumab prophylaxis treatment, compared to 9.8 in the on-demand treatment group Estimated mean ABR was 1.7 for concizumab prophylaxis treatment, compared to 11.8 in the on-demand treatment group For patients on concizumab prophylaxis, 64% had 0 bleeds in Group 2 Safety Concizumab appeared to have a safe and well tolerated profile Status • • US Complete Response Letter for HwI received in Q2 2023 EU submission for inhibitor indications completed in Q1 2023 JP submission for inhibitor indications completed in Q3 2022 Explorer8 in non-inhibitor patients is completed in Q3 2022 Primary endpoint Note: The box represents Q1-Q3 (25th to 75th percentile). Whiskers are 5th and 95th percentile. HA: Haemophilia A; HB: Haemophilia B; HAWI: Haemophilia A with inhibitors, HBWI: Haemophilia B with inhibitors; OnD: On-demand; PPX: Prophylaxis; ABR annualised bleeding rate

View entire presentation